Celladon Raises $400K
San Diego-based Celladon, which is developing drug candidates that target a key enzyme deficiency apparent in heart failure, has secured $400,000 in a debt and securities financing, according to a recent regulatory filing. In late June, Celladon said a clinical study of its lead candidate, which is intended to restore a key enzyme that regulates calcium cycling and contractility in the heart, met its primary safety and efficacy endpoints at six months. The company has raised more than $60 million, according to Dow Jones VentureWire. On its website, Celladon identifies its current investors as as Enterprise Partners Venture Capital, Venrock, and Johnson & Johnson.